New Biomarkers May Predict Failure of Treatment in Metastatic Prostate Cancer
Blood-based biomarkers such as platelets, CRP, and chromogranin A may help predict treatment failure in metastatic prostate cancer, enabling personalized therapeutic strategies.
Recent research has uncovered blood-based biomarkers that could help predict the likelihood of treatment failure in patients with metastatic prostate cancer, including both hormone-sensitive and castration-resistant forms. Published in The Journal of Molecular Diagnostics, the study highlights the significance of markers such as platelets, C-reactive protein (CRP), and chromogranin A in hormone-sensitive prostate cancer patients undergoing combined androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI). For castration-resistant cases, microRNA-375 (miR-375) and lymphocyte-to-monocyte ratio (LMR) were identified as key predictors.
The study involved analyzing plasma samples from 140 patients before starting ARPI therapy. Using digital PCR, researchers measured androgen receptor (AR) gene amplification, while quantitative PCR assessed miR-375 levels. Additionally, 16 clinical markers, including prostate-specific antigen (PSA), chromogranin A, alkaline phosphatase, lactate dehydrogenase, and others, were evaluated.
Findings revealed that in castration-resistant prostate cancer, elevated miR-375 levels and lower LMR independently predicted therapy failure. For hormone-sensitive prostate cancer, higher levels of platelets, CRP, and chromogranin A were associated with poorer treatment outcomes. These biomarkers are important because they may reflect the tumor’s biology and the immune environment, influencing treatment response.
Particularly noteworthy is the role of platelets, which facilitate metastasis by supporting tumor cell survival and growth. The study emphasizes that measuring these blood-based markers can aid clinicians in monitoring disease progression and adjusting therapies more effectively. With further validation, these findings could lead to more personalized and timely treatment strategies for patients with advanced prostate cancer.
Lead researcher Dr. Jan Bouchal from Palacký University highlights that these markers are accessible and easily implemented in clinical laboratories, making them promising tools for improving patient management. The integration of such biomarkers into routine practice could significantly enhance the prediction of treatment outcomes and guide decisions for more aggressive or alternative therapies.
Source: https://medicalxpress.com/news/2025-05-analysis-markers-failure-metastatic-prostate.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Elevated Lead Exposure Associated with Decline in Academic Performance in Children
New study finds that even low levels of lead in children can significantly reduce academic achievement, highlighting the need for stricter prevention measures.
New Cellular Atlas Uncovers Key Insights into Prostate Cancer Response and Resistance Mechanisms
A novel cellular atlas sheds light on the mechanisms of prostate cancer response and resistance to androgen deprivation therapy, offering new avenues for targeted treatments and overcoming therapy resistance.
States Reduce Medicaid Payments Long Before Federal Cuts Take Effect
Many U.S. states are cutting Medicaid provider payments ahead of federal funding reductions, risking healthcare access for vulnerable populations amid budget challenges.
Understanding Sex Differences in Neurological Disorders
Recent research highlights how sex influences dopamine regulation in the brain, opening new avenues for personalized treatments of neurological and psychiatric conditions such as TS, schizophrenia, and ADHD.